Toxicology – Fomepizole (4-Methylpyrazole)

Core Concept

Fomepizole is the preferred antidote for clinically important methanol and ethylene glycol poisoning.

It works by inhibiting alcohol dehydrogenase (ADH), preventing these parent alcohols from being converted into their more dangerous metabolites.

The key principle is:

Fomepizole prevents further toxic-metabolite formation; it does not directly remove metabolites that have already accumulated.

For severe poisoning, hemodialysis may still be required.

Mechanism of Action

Methanol and ethylene glycol initially have relatively limited intrinsic toxicity compared with their metabolites.

Alcohol dehydrogenase initiates their metabolism.

Fomepizole is a potent competitive inhibitor of ADH:

ADH inhibition → ↓ toxic alcohol metabolism → ↓ formation of toxic metabolites

This allows the unchanged parent alcohol to remain available for elimination or removal by dialysis.

Methanol Metabolism

Methanol undergoes:

Methanol → formaldehyde → formic acid/formate

Formate is responsible for much of the severe toxicity, particularly:

• High-anion-gap metabolic acidosis
• Mitochondrial dysfunction
• Optic nerve injury
• Retinal toxicity
• Visual impairment
• CNS injury

Fomepizole prevents additional formation of formate.

Ethylene Glycol Metabolism

Ethylene glycol undergoes:

Ethylene glycol → glycolaldehyde → glycolate → glyoxylate → oxalate

Important toxic consequences include:

• High-anion-gap metabolic acidosis
• Hypocalcemia
• Calcium oxalate formation
• Acute kidney injury
• Neurologic and cardiovascular toxicity

Glycolate is particularly important in producing the metabolic acidosis.

Why Fomepizole Is Preferred Over Ethanol

Both ethanol and fomepizole inhibit toxic-alcohol metabolism.

However, fomepizole offers several practical advantages:

• More predictable ADH inhibition
• Easier administration
• No therapeutic ethanol intoxication
• Less CNS depression
• Lower risk of hypoglycemia
• No need to maintain a therapeutic blood ethanol concentration
• Fewer fluid-management problems
• Easier use in critically ill patients

Therefore:

Fomepizole has largely replaced ethanol as the preferred ADH inhibitor when available.

When to Consider Fomepizole

Treatment should be considered when methanol or ethylene glycol poisoning is sufficiently suspected from findings such as:

• Credible toxic exposure
• Detectable toxic-alcohol concentration of concern
• High-anion-gap metabolic acidosis compatible with toxic alcohol exposure
• Elevated osmolal gap in the appropriate setting
• Characteristic organ toxicity

Treatment decisions should integrate the whole clinical picture rather than rely on one historical concentration cutoff.

Do Not Delay Treatment in a High-Risk Patient

Confirmatory toxic-alcohol concentrations may take considerable time to return.

When serious methanol or ethylene glycol poisoning is strongly suspected:

Fomepizole should be started promptly rather than waiting for definitive laboratory confirmation.

This is particularly important because toxic metabolites may continue to accumulate while testing is pending.

Osmolal Gap

Early in poisoning, unmetabolized parent alcohol may substantially increase the osmolal gap.

As metabolism proceeds:

Parent alcohol ↓ → osmolal gap may ↓

while:

Acidic metabolites ↑ → anion gap ↑

Therefore:

A normal osmolal gap does not exclude methanol or ethylene glycol poisoning, especially later after exposure.

Anion Gap

The development of high-anion-gap metabolic acidosis often reflects accumulation of toxic metabolites.

Important contributors include:

• Formate in methanol poisoning
• Glycolate in ethylene glycol poisoning

However, the anion gap is neither completely sensitive nor specific and must be interpreted with exposure history and other laboratory findings.

Effect of Fomepizole on Toxic-Alcohol Kinetics

Once ADH is inhibited, metabolism slows dramatically.

This is beneficial because toxic metabolite formation stops, but it also means the parent alcohol can remain in the body much longer.

Without dialysis:

Parent toxic-alcohol half-life becomes prolonged.

This does not mean fomepizole has failed; it reflects successful blockade of metabolism.

Methanol Poisoning

Important manifestations can include:

• Nausea and vomiting
• Headache
• Abdominal discomfort
• CNS depression
• High-anion-gap metabolic acidosis
• Blurred vision
• Photophobia
• Visual-field abnormalities
• Severe visual impairment
• Coma in advanced poisoning

Fomepizole prevents further formate production but cannot instantly reverse established optic injury.

Ethylene Glycol Poisoning

Possible manifestations include:

• CNS depression
• Nausea and vomiting
• Tachycardia
• Metabolic acidosis
• Hypocalcemia
• Muscle spasms or tetany
• Seizures in severe cases
• Acute kidney injury

Urinary calcium oxalate crystals may support the diagnosis but are neither required nor sufficiently specific to establish it.

Fomepizole Does Not Correct Existing Acidosis

If substantial toxic metabolites have already accumulated, simply blocking ADH may not rapidly correct the resulting metabolic acidosis.

Management may also require:

• Supportive resuscitation
• Correction of severe acid-base abnormalities
• Electrolyte management
• Hemodialysis when indicated

Hemodialysis

Hemodialysis efficiently removes methanol and ethylene glycol and can remove important circulating toxic metabolites.

It also rapidly corrects:

• Severe metabolic acidosis
• Major electrolyte abnormalities

Dialysis is considered in selected severe poisoning based on factors such as:

• Significant metabolic acidosis
• Serious clinical deterioration
• Visual toxicity from methanol
• Significant kidney injury in ethylene glycol poisoning
• High toxic-alcohol burden
• Other accepted extracorporeal-treatment indications

Modern decisions should use current toxicology and extracorporeal-treatment guidance rather than a single old concentration threshold.

Fomepizole During Hemodialysis

Fomepizole itself is removed by hemodialysis.

Therefore, its administration schedule must be modified during intermittent hemodialysis to maintain adequate ADH inhibition.

The exact adjustment depends on the dialysis modality and current treatment protocol.

Continuous Kidney Replacement Therapy

Continuous extracorporeal therapies differ from intermittent hemodialysis in their clearance of fomepizole and toxic alcohols.

Dose adjustment therefore should not simply copy an intermittent-hemodialysis regimen.

Current poison-center, nephrology, pharmacy, or toxicology guidance should be followed.

Folate in Methanol Poisoning

Methanol metabolism produces formate.

Folic acid or leucovorin may be used as an adjunct because folate-dependent pathways facilitate conversion of formate toward carbon dioxide and water.

Folate does not replace:

• Fomepizole
• Correction of severe acidosis
• Dialysis when indicated

Adjuncts in Ethylene Glycol Poisoning

Thiamine and pyridoxine have historically been administered to favor metabolism of glyoxylate toward less toxic products.

Their clinical importance is secondary to:

• ADH inhibition
• Supportive care
• Management of acidosis
• Hemodialysis when required

They should never delay definitive therapy.

Concurrent Ethanol

Ethanol also competes for alcohol dehydrogenase.

A patient who has simultaneously consumed ethanol may therefore show delayed development of methanol or ethylene glycol toxicity.

As ethanol disappears:

ADH becomes available → toxic alcohol metabolism increases → toxic metabolites accumulate

Thus an initially well-appearing patient can subsequently deteriorate.

Fomepizole and Ethanol Together

Concurrent ethanol exposure is not, by itself, a reason to withhold fomepizole when fomepizole is clinically indicated.

Fomepizole can inhibit ethanol metabolism and prolong ethanol elimination.

The older concept that a measurable ethanol concentration constitutes an absolute contraindication to fomepizole is therefore too rigid.

Clinical monitoring is required.

Adverse Effects

Fomepizole is generally well tolerated.

Reported effects include:

• Headache
• Nausea
• Dizziness
• Vertigo
• Gastrointestinal symptoms
• Mild transient liver-enzyme abnormalities
• Injection-related reactions

Serious adverse effects are uncommon relative to the consequences of untreated toxic-alcohol poisoning.

Hypersensitivity

Fomepizole should be used cautiously or avoided in patients with a convincing history of serious hypersensitivity to:

• Fomepizole
• Closely related pyrazole compounds

In life-threatening toxic-alcohol poisoning, management requires immediate specialist consideration of alternative ADH blockade and extracorporeal therapy.

Pregnancy

The historical FDA Category C classification is obsolete.

Methanol and ethylene glycol can cause severe maternal and fetal toxicity.

Therefore:

Necessary treatment should not be withheld solely because the patient is pregnant.

Fomepizole may be used when the expected benefit of preventing toxic-metabolite formation outweighs potential treatment risk.

Maternal stabilization is the priority.

Pediatric Poisoning

The same fundamental toxicology applies in children:

Prevent toxic-metabolite formation early.

Children with significant suspected methanol or ethylene glycol poisoning require urgent specialist management.

Treatment is based on weight, clinical severity, laboratory abnormalities, and extracorporeal therapy requirements.

Monitoring

Important monitoring includes:

• Mental status
• Airway and ventilation
• Blood pressure and perfusion
• Blood gas
• Bicarbonate
• Anion gap
• Electrolytes
• Glucose
• Renal function
• Osmolality/osmolal gap when useful
• Methanol or ethylene glycol concentration when available

Additional monitoring depends on the suspected alcohol.

Methanol-Specific Monitoring

Pay particular attention to:

• Visual symptoms
• Visual acuity when feasible
• Neurologic deterioration
• Severity of metabolic acidosis

Severe visual toxicity is an important marker of clinically significant formate exposure.

Ethylene Glycol-Specific Monitoring

Pay particular attention to:

• Creatinine
• Urine output
• Calcium
• Neuromuscular manifestations of hypocalcemia
• Evidence of acute kidney injury

Urinary crystals may be sought but should not determine treatment by themselves.

Stopping Fomepizole

Therapy should not be stopped merely because the patient appears clinically improved.

Discontinuation depends on factors such as:

• Toxic-alcohol concentration
• Resolution of clinically important acidosis
• Clinical stability
• Completion of dialysis when applicable
• Confidence that ongoing toxic-metabolite production is no longer clinically important

Current institutional or poison-center protocols should guide the endpoint.

Important Modernization of the Older Source

• Fomepizole is generally the preferred antidote for methanol and ethylene glycol poisoning.
• It inhibits alcohol dehydrogenase and prevents formation of additional toxic metabolites.
• It does not directly neutralize formate, glycolate, or oxalate already produced.
• Severe poisoning may therefore still require hemodialysis despite timely fomepizole.
• Treatment should not be delayed for confirmatory toxic-alcohol levels when clinical suspicion is high.
• A normal osmolal gap does not exclude late poisoning.
• The osmolal gap tends to be more prominent while parent alcohol remains, whereas the anion gap rises as acidic metabolites accumulate.
• Historical fixed concentration thresholds should not be used as the sole basis for starting antidote or dialysis.
• Fomepizole substantially prolongs the elimination of unmetabolized methanol and ethylene glycol when dialysis is not performed.
• Hemodialysis removes fomepizole, so the administration schedule must be adjusted during extracorporeal therapy.
• Concurrent ethanol is not an absolute contraindication to fomepizole.
• Fomepizole can slow ethanol elimination.
• Folate is an adjunct for methanol poisoning.
• Thiamine and pyridoxine are secondary adjuncts in ethylene glycol poisoning and should not distract from definitive treatment.
• Historical FDA pregnancy categories are obsolete.
• Exact dosing and dialysis adjustments should follow current toxicology, pharmacy, and extracorporeal-treatment protocols rather than older fixed regimens.

Key Points

• Fomepizole inhibits alcohol dehydrogenase.
• It is the preferred antidote for significant methanol and ethylene glycol poisoning.
• Methanol toxicity is largely caused by formate, particularly producing acidosis and optic toxicity.
• Ethylene glycol toxicity is largely caused by metabolites including glycolate and oxalate, producing acidosis and renal injury.
• Fomepizole prevents additional toxic-metabolite formation but does not remove metabolites already present.
• A normal osmolal gap does not exclude toxic-alcohol poisoning.
• Do not delay treatment in a strongly suspected severe exposure while waiting for definitive levels.
• Hemodialysis may still be necessary for severe poisoning.
• Fomepizole is dialyzable, requiring protocol-specific adjustment during hemodialysis.
• Folate is an adjunct in methanol poisoning.
• Concurrent ethanol can delay toxic-alcohol manifestations and can itself persist longer after fomepizole.
• Fomepizole is generally safer and easier to manage than therapeutic ethanol.